Chinese Journal of Practical Pediatrics ›› 2021, Vol. 36 ›› Issue (9): 655-660.DOI: 10.19538/j.ek2021090604
Previous Articles Next Articles
Online:
Published:
通讯作者:
Abstract: Atopic dermatitis is a kind of chronic recurrent inflammatory skin disease. The mild-to-moderate pediatric AD is managed by topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs),but there are great challenges in the treatment of moderate-to-severe pediatric AD. In addition to systemic immunesuppressants,biological agents and smallmolecule inhibitors have been used gradually in clinical practice. We reviewed the latest progress in new systemic agents in treatment of pediatric AD.
Key words: child, atopic dermatitis, systemic treatment, immunosuppresive agents, small molecule drugs
摘要: 特应性皮炎(atopic dermatitis,AD)是一种慢性、复发性、炎症性皮肤病。轻中度儿童AD的治疗通常以外用糖皮质激素、钙调磷酸酶抑制剂为主,但中重度儿童AD的治疗具有挑战性。除了传统免疫抑制剂系统治疗外,生物制剂及小分子靶向抑制剂逐渐应用于临床。该文就儿童AD系统药物治疗的最新进展进行综述。
关键词: 儿童, 特应性皮炎, 系统治疗, 免疫抑制剂, 小分子药物
GU Yang, QIAN Hua. Research progress in systemic agents in the treatment of pediatric atopic dermatitis[J]. Chinese Journal of Practical Pediatrics, 2021, 36(9): 655-660.
顾 洋, 钱 华. 儿童特应性皮炎系统药物治疗研究进展[J]. 中国实用儿科杂志, 2021, 36(9): 655-660.
0 / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgsyz.com/zgsyek/EN/10.19538/j.ek2021090604
http://www.zgsyz.com/zgsyek/EN/Y2021/V36/I9/655